Press Releases

AGF Reports April 2024 Assets Under Management and Fee-Earning Assets May 3, 2024 05:02PM

TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- AGF Management Limited reported total assets under management (AUM) and fee-earning assets1 of $47.8 billion as at April 30, 2024.

AUM($ billions)April 30, 2024March 31,2024% ChangeMonth-Over-MonthApril 30,2023% ChangeYear-Over-YearTotal Mutual Fund$26.2$26.7 $24.2 Exchange-traded funds + Separately managed accounts$1.9$1.7 $1.4 Segregated accounts and Sub-advisory$7.2$7.4 $7.2 AGF Private Wealth$7.8$8.0 $7.4 Subtotal... (continue reading...)

Radio Fuels Appoints Bill de Jong as Director May 3, 2024 05:00PM

Toronto, Ontario--(Newsfile Corp. - May 3, 2024) - Radio Fuels Energy Corp.(CSE: CAKE) (OTCQB: CKEFF) (the "Company" or "Radio Fuels") is pleased to announce the appointment of Bill de Jong as Director of the Company effective immediately.

Bill de Jong is a lawyer in the Capital Markets group with international law firm DLA Piper (Canada) LLP, with a focus on the natural resources and energy sectors. He maintains a practice specializing in the areas of securities... (continue reading...)

Canadian Natural Resources Limited Reports Voting Results at Annual and Special Meeting May 3, 2024 05:00PM

Calgary, Alberta--(Newsfile Corp. - May 3, 2024) - Canadian Natural Resources Limited (TSX: CNQ) (NYSE: CNQ) held its Annual and Special Meeting of Shareholders on May 2, 2024. The result of the vote by shareholders for each resolution is reported below.

The election of the following nominees as directors of the Corporation for the ensuing year or until their successors are elected or appointed.

Votes ForVotes Withheld Catherine M. Best739,666,79497.19%21,395,0272.81% ... (continue reading...)

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals May 3, 2024 05:00PM

Sentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases

Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients

SOLANA BEACH, Calif. and AHMEDABAD, India and PALO ALTO, Calif., May 3,... (continue reading...)

Spyre Therapeutics Announces Grants of Inducement Awards May 3, 2024 05:00PM

WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an... (continue reading...)